Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon TLR7/8 Agonist Neoadjuvant Therapy in Head and Neck Cancer
NCT05980598Phase 2Terminated
- Sponsor
- Ascendis Pharma
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of ACP-017 in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Major Pathological Response. Started Sep 2023; status: terminated.
02
Drugs
ACP-017
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05980598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980598.